The AI Validation Divide: FDA Flexibility vs. EU Control in GxP Systems

On this episode of The Regulatory Mix, the discussion focuses on one of the most difficult questions facing regulated life sciences: how do you validate a system that may not give you the exact same answer twice?

As generative AI and machine learning move deeper into pharmaceutical, medical device, and GxP environments, regulators are beginning to take different approaches to managing that uncertainty. The emerging U.S. approach places greater emphasis on demonstrated performance, predefined acceptance criteria, benchmarking, real-world monitoring, and continued assessment for model drift. The European approach reflected in developing Annex 22 expectations is more conservative for critical GMP applications, emphasizing static or locked models, reproducibility, and strong limitations on the use of generative AI where outputs could directly affect product quality or patient safety.

The episode explores why this distinction matters. Traditional computerized system validation was built largely around deterministic software: defined inputs, expected outputs, and repeatable test results. Large language models challenge that paradigm because variability is inherent to the technology. The regulatory question therefore becomes whether reproducibility must be designed into the architecture itself or whether variability can instead be characterized, bounded, monitored, and controlled statistically.

The discussion also examines the proposed modernization of EU GMP Annex 11 and what it means beyond AI. Lifecycle validation, Quality Risk Management, requirements traceability, data integrity, access controls, supplier oversight, change management, and continued validated-state maintenance remain foundational expectations regardless of the technology being deployed. Using a cloud provider, commercial AI platform, or third-party foundation model does not transfer regulatory accountability away from the regulated company.

Human oversight is another central issue. A person approving an AI output is not necessarily an effective control if that individual lacks the domain knowledge or AI literacy needed to recognize when the system is wrong. Meaningful human-in-the-loop oversight therefore requires both technical understanding and subject-matter expertise, as well as awareness of automation bias and the natural tendency to trust confident machine-generated answers.

The takeaway is that AI does not eliminate traditional validation principles—it puts pressure on them. The industry now has to determine how concepts such as intended use, risk, traceability, change control, supplier qualification, data integrity, and continued verification apply to systems whose behavior may be probabilistic rather than fixed. The firms that solve this problem will not simply be the ones adopting AI fastest, but those that can demonstrate that its variability is understood, controlled, and appropriate for its intended GxP use.

Sponsored by Tailwind Pharma, LLC, a pharmaceutical quality and regulatory consulting firm specializing in FDA inspections, CGMP compliance, sterile manufacturing, data integrity, investigations, and regulatory strategy. Learn more at tailwindconsult.com.

Disclaimer: The views expressed are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.